EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon α-accelerated murine lupus

Paul M Gallo, Robert W Chain, Jun Xu, Leah M Whiteman, Annette Palladino, Roberto Caricchio, Patricia Costa-Reis, Kathleen E Sullivan, Stefania Gallucci

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Paul M Gallo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Dendritic Cell Biology, Department of Microbiology and Immunology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 1…. Hauptthemen laut MEDLINE: Lapatinib, Erb-b2 Receptor Tyrosine Kinases, ErbB Receptors, Interferon-alpha. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glomerulonephritis remains a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We have reported that expression of HER2/ErbB2, a member of the EGFR family, is increased in kidneys of patients and mice with lupus nephritis. We therefore asked if EGFR-family inhibition could ameliorate murine lupus nephritis. We used lapatinib, an EGFR-ErbB2 dual kinase inhibitor in female lupus-prone NZBxW/F1 mice, in which lupus onset was accelerated by injecting an IFN-α-expressing adenovirus. Mice received lapatinib (75 mg/Kg) or vehicle from the beginning of the acceleration or after the mice developed severe proteinuria (>300 mg/dL). Autoantibodies, kidney disease and markers of fibrosis and wound healing were analyzed. Exposure to IFNα induced ErbB2 expression in the kidney of lupus prone mice. Lapatinib, administered before but not after renal disease onset, lowered autoantibody titers and lessened immune complex deposition in the kidney. However, lapatinib increased proteinuria, kidney fibrosis and mouse mortality. Lapatinib also inhibited an in vitro wound healing assay testing renal cells. Our results suggest that EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoimmunity but worsens renal disease in IFNα-accelerated lupus, by increasing fibrosis and inhibiting wound healing. Type I Interferons are highlighted as important regulators of HER2/ErbB2 expression in the kidney. Further studies are required to parse the beneficial aspects of EGFR inhibition on autoimmunity from its negative effects on wound healing in lupus nephritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LapatinibErb-b2 Receptor Tyrosine KinasesErbB ReceptorsInterferon-alphaAutoantibodiesProtein Kinase InhibitorsLupus NephritisAnimalsFemaleMiceKidneyHumansFibrosisLupus Erythematosus, SystemicDisease Models, AnimalQuinazolinesMice, Inbred NZB

Stichwörter der Autor:innen

AutoantibodiesEGFR/HER2 inhibitorFibrosisLupusNephrotoxicitytype I IFN

Substanzen

LapatinibErb-b2 Receptor Tyrosine KinasesErbB ReceptorsInterferon-alphaAutoantibodiesProtein Kinase InhibitorsQuinazolinesErbb2 protein, mouseEGFR protein, mouse

Autor:innen und Institutionen

  • Laboratory of Dendritic Cell Biology, Department of Microbiology and Immunology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
  • Division of Innate Immunity, Department of Medicine, UMass Chan Medical School, Worcester, MA, USA.
  • Section of Rheumatology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
  • Division of Allergy Immunology, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Laboratory of Dendritic Cell Biology, Department of Microbiology and Immunology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA; Division of Innate Immunity, Department of Medicine, UMass…

Förderung

  • NIAID NIH HHS
  • NIAMS NIH HHS

Zitieren

APA

Gallo, P. M., Chain, R. W., Xu, J., Whiteman, L. M., Palladino, A., Caricchio, R., Costa-Reis, P., Sullivan, K. E., & Gallucci, S. (2024). EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon α-accelerated murine lupus. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112692

Vancouver

Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, et al. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon α-accelerated murine lupus. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112692

BibTeX
@article{Gallo2024,
  author = {Gallo, Paul M and Chain, Robert W and Xu, Jun and Whiteman, Leah M and Palladino, Annette and Caricchio, Roberto and Costa-Reis, Patricia and Sullivan, Kathleen E and Gallucci, Stefania},
  title = {EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon α-accelerated murine lupus},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112692}
}
Kostenlos starten →